PDL BioPharma Inc
932 Southwood Blvd.
Incline Village
NV
89451
United States
39 articles about PDL BioPharma Inc
-
PDL BioPharma Enters into $51.4 Million Capital Provision Agreement with Epps Investments LLC Regarding PDL's Previously Announced Settlement Agreement with Wellstat
12/14/2020
PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces it has entered into a Capital Provision Agreement (the "Agreement") with Epps Investments LLC ("Epps"). Under the terms of the Agreement, Epps will pay PDL $51,391,184 no later than December 31, 2020 , in exchange for 100% of the payments or other property or va
-
PDL Announces Timeline for Voluntarily Delisting from Nasdaq
12/8/2020
Trading in PDL's Common Stock on Nasdaq to be Suspended Prior to Market Opening on December 31, 2020
-
PDL BioPharma Reports 2020 Third Quarter Financial Results and Sets Date To File a Certificate of Dissolution
11/11/2020
PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) reports financial results for the three and nine months ended September 30, 2020 and provides an update on important milestones achieved in the execution of its monetization and liquidation plan.
-
PDL BioPharma Reschedules Third Quarter 2020 Financial Results and Business Update
11/6/2020
PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces it has rescheduled the date for announcing third quarter 2020 financial results and holding a conference call to Wednesday, November 11 , 2020. PDL will issue
-
PDL BioPharma to Announce Third Quarter 2020 Financial Results and Provide a Business Update on November 9, 2020
10/29/2020
- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces that it will release its third quarter 2020 financial results for the period ended September 30, 2020 , on Monday, November 9, 2020 after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern time to dis
-
PDL BioPharma Completes Spin-Off of LENSAR
10/2/2020
PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that it has completed the previously announced spin-off of its femtosecond laser system business, LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR"). PDL stockholders received 0.075879 shares of LENSAR common stock for every one share of PDL common stock outs
-
PDL BioPharma to Complete Spin-Off of LENSAR, Inc. on October 1, 2020
9/10/2020
Declares Record Date of September 22, 2020 and Expected Share Distribution Date of October 1, 2020 Conference call with slide presentation today beginning at 4:30 p.m. Eastern time [10-September-2020] INCLINE VILLAGE, Nev. , Sept. 10, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announced that its Board of Directors has ap
-
PDL BioPharma Completes Divestiture of the Noden Pharmaceutical Business to Stanley Capital
9/9/2020
PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the closing of the sale of its wholly owned subsidiaries Noden Pharma DAC and Noden Pharma USA (collectively "Noden") to Stanley Capital. The total value of the transaction will result in payments to PDL of up to $52.83 million in cash, $4.58 milli
-
PDL BioPharma Announces Sale of Kybella®, Zalviso® and Coflex® Royalties to SWK Holdings Corporation
8/31/2020
PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the signing and closing of a definitive agreement for the sale of three royalty interests for Kybella ® , Zalviso ® , and Coflex ® (collectively the "Royalties") to SWK Funding, LLC ("SWK"), a wholly owned subsidiary of SWK Holdings Corporation (Nasdaq: SW
-
PDL BioPharma Announces Filing of a Form 10 Registration Statement with the Securities and Exchange Commission for a Potential Spin-off of LENSAR to PDL's Stockholders
8/26/2020
PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces that its majority owned medical device subsidiary, LENSAR, Inc. ("LENSAR"), has filed a registration statement on Form 10 with the Securities and Exchange Commission relating to a potential spin-off of LENSAR from PDL.
-
PDL BioPharma Enters Into Settlement Agreement with Wellstat
8/12/2020
PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces it has entered into a settlement agreement (the "Settlement Agreement") with related entities of Defined Diagnostics, LLC (f/k/a Wellstat Diagnostics, LLC) ("Wellstat Diagnostics" and, together with such related entities, the "Wellstat Parties") r
-
PDL BioPharma Reports 2020 Second Quarter Financial Results
8/6/2020
PDL BioPharma, Inc. reports financial results for the three and six months ended June 30, 2020 and provides an update on important milestones achieved in the execution of its monetization plan
-
PDL BioPharma Enters Into Agreement for the Divestiture of the Noden Pharmaceutical Business to Stanley Capital
7/30/2020
PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the signing of a definitive agreement for the sale of 100% of the outstanding stock in its wholly owned subsidiaries Noden Pharma DAC and Noden USA (collectively "Noden") to Stanley Capital ("Stanley Capital"). The total value of the transaction will resul
-
PDL BioPharma to Announce Second Quarter 2020 Financial Results on August 6, 2020
7/30/2020
PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces that it will release its second quarter 2020 financial results for the period ended June 30, 2020, on Thursday, August 6, 2020, after market close.
-
PDL BioPharma Completes Distribution of Evofem Biosciences Common Stock to PDL Stockholders
5/21/2020
PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces that it has completed its previously announced distribution of all of the Company's 13,333,334 shares of common stock of Evofem Biosciences, Inc. ("Evofem") (Nasdaq: EVFM), which represented approximately 26.7% of the outstanding shares of Evofem common stock a
-
PDL BioPharma Declares Distribution Ratio for Dividend of Evofem Biosciences Common Stock to PDL Stockholders
5/18/2020
PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the final distribution ratio for the previously announced distribution of all of the Company's 13,333,334 shares of common stock of Evofem Biosciences, Inc. (
-
PDL BioPharma Declares Dividend of Evofem Biosciences Common Stock to PDL Stockholders
5/5/2020
PDL BioPharma, Inc. announces that the Company's Board of Directors has approved a distribution of all of the Company's 13,333,334 shares of common stock of Evofem Biosciences, Inc. via a special one-time dividend to PDL stockholders.
-
PDL BioPharma to Announce First Quarter 2020 Financial Results on May 7, 2020
4/30/2020
PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces that it will release its first quarter 2020 financial results for the period ended March 31, 2020 , on Thursday, May 7, 2020 , after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern time to discu
-
PDL BioPharma Reports 2019 Fourth Quarter and Full Year Financial Results and Announces Plan to Dissolve the Company by Year-End 2020
3/11/2020
PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) provides an update on its strategic plans and reports financial results for the three and twelve months ended December 31, 2019:
-
PDL BioPharma Announces Appointment of Edward A. Imbrogno as Vice President and Chief Financial Officer
3/9/2020
PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced the appointment of Edward A. Imbrogno as the Company's Vice President and Chief Financial Officer. Mr. Imbrogno jo